Glybera

Type: Product
Name: Glybera
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

With Strong Corporate Partnerships, Xenon Pharmaceuticals IPO Looks Appealing

Summary XENE recently filed for an approximately $44 million NASDAQ IPO; XENE will offer 4 million shares at a target high price of $12. XENE is a clinical stage biopharmaceutical company that is focused on developing a pipeline of treatments for genetically ... [Published Seeking Alpha - Oct 17 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

RNCOS - Business Consulting Services: Groundbreaking Gene Therapy Trials Offering Hope to Blind Patients

According to a new research report by RNCOS entitled, "Global Gene Therapy Market Outlook 2018", the advancement of gene therapy for eye disorders is likely to prove to be one of the greatest medical advances in the coming years, as industry participants ... [Published BusinessWeek - Oct 15 2014]
First reported Oct 13 2014 - Updated Oct 14 2014 - 1 reports

7 US IPOs planned for the week of October 13, including the IPO market's biotech test

Seven initial public offerings are expected to raise $1.7 billion in the upcoming week. Four IPOs are biotechs, including Forward Pharma, which could be the year's largest (and 60th), and three others in early stages of development. Consolidated fiber ... [Published Nasdaq - Oct 13 2014]
First reported Oct 03 2014 - Updated Oct 04 2014 - 1 reports

Forbion Capital Partners Announces First Close Of FCF III

- Forbion Capital Partners (Forbion) today announced that it has raised EUR 92m (USD 120m) in a first close of its new fund FCF III.FCF III will invest in 12-15 companies, managed by Forbion’s partners Sander Slootweg, Martien van Osch, Sander van Deventer, ... [Published BioSpace - Oct 03 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

uniQure to Present at the Leerink Partners Rare Disease Roundtable Conference

Amsterdam, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present at the Leerink Partners Rare Disease Roundtable Conference, October 1st, 2014, ... [Published Pettinga Financial Advisors - Sep 25 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

EmTech: Risks of Gene-Editing Drugs Need Study, Pioneer Says

Feng ZhangCiting the risk of deadly mistakes, a leading researcher speaking at MIT Technology Review’s  EmTech conference  on Tuesday said the risks of gene editing need to be better understood before the technology can be used in medical studies.Feng ... [Published Technology Review - Sep 24 2014]
First reported Sep 14 2014 - Updated Sep 14 2014 - 1 reports

Gene Therapies Push Investors to Examine New Areas of Human Body

Advances in gene therapy are leading venture investors to fund treatments for conditions affecting a wider range of body systems. Venture firms have sunk more dollars into gene therapies since 2010, $715.8 million, than they did all of last decade, ... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 3 reports

Xenon pitches Genentech, Teva 'extreme genetics' ties as it rolls out a $52M IPO

Xenon Pharmaceuticals has gone 8 long years since its last equity raise, relying on a slate of partnerships with some of the biggest names in the business to fund its work. And now it's set out to test the fall biotech IPO market with a $52 million offering ... [Published FierceBiotech - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 1 reports

Human medicines European public assessment report (EPAR): Glybera, alipogene tiparvovec, Revision: 1, Authorised

First reported Jun 18 2014 - Updated Jun 19 2014 - 2 reports

uniQure, Medison sign distribution agreement for Glybera

uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ... [Published PBR - News - Jun 19 2014]

Quotes

"Glybera represents an exciting opportunity for Medison to continue its leadership in offering new innovative treatments in Israel"

More Content

All (19) | News (13) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
With Strong Corporate Partnerships, Xenon Pharm... [Published Seeking Alpha - Oct 17 2014]
RNCOS - Business Consulting Services: Groundbre... [Published BusinessWeek - Oct 15 2014]
7 US IPOs planned for the week of October 13, i... [Published Nasdaq - Oct 13 2014]
Forbion Capital Partners Announces First Close ... [Published BioSpace - Oct 03 2014]
uniQure to Present at the Leerink Partners Rare... [Published BizWire Express - Sep 25 2014]
uniQure to Present at the Leerink Partners Rare... [Published Pettinga Financial Advisors - Sep 25 2014]
EmTech: Risks of Gene-Editing Drugs Need Study,... [Published Technology Review - Sep 24 2014]
Gene Therapies Push Investors to Examine New Ar... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
Xenon pitches Genentech, Teva 'extreme genetics... [Published FierceBiotech - Sep 10 2014]
Rare Disease Biotech Xenon Pharmaceuticals Inc.... [Published BioSpace - Sep 10 2014]
Rare disease biotech Xenon Pharmaceuticals file... [Published Renaissance Capital - Sep 10 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Sep 03 2014]
Chiesi and uniQure Provide Update on Glybera(r)... [Published GlobeNewswire: Acquisitions News - Aug 04 2014]
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
uniQure and Medison Sign Glybera Distribution A... [Published PR Newswire - Jun 18 2014]
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
Gene Expression Analysis Market (Gene Profiling... [Published PRWeb - Mar 27 2014]
Europe: Early Communications with Regulators is... [Published Pharmaceutical Executive - Jan 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Gene Therapies Push Investors to Examine New Ar... [Published WSJ.com: Venture Capital Dispatch - Sep 14 2014]
Advances in gene therapy are leading venture investors to fund treatments for conditions affecting a wider range of body systems. Venture firms have sunk more dollars into gene therapies since 2010, $715.8 million, than they did all of last decade, ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Sep 03 2014]
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ...
1

Press Releases

sort by: Date | Relevance
Chiesi and uniQure Provide Update on Glybera(r)... [Published GlobeNewswire: Acquisitions News - Aug 04 2014]
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.